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Identifying the best drug for each cancer patient requires an efﬁcient individualized strategy.
We present MATCH (Merging genomic and pharmacologic Analyses for Therapy CHoice), an
approach using public genomic resources and drug testing of fresh tumor samples to link drugs to
patients. Valproic acid (VPA) is highlighted as a proof-of-principle. In order to predict speciﬁc tumor
types with high probability of drug sensitivity, we create drug response signatures using publically
available gene expression data and assess sensitivity in a data set of 440 cancer types. Next, we
evaluate drug sensitivity in matched tumor and normal tissue and exclude cancer types that are no
more sensitive than normal tissue. From these analyses, breast tumors are predicted to be sensitive
to VPA. A meta-analysis across breast cancer data sets shows that aggressive subtypes are most
likely to be sensitive to VPA, but all subtypes have sensitive tumors. MATCH predictions correlate
signiﬁcantly with growth inhibition in cancer cell lines and three-dimensional cultures of fresh
tumorsamples.MATCHaccuratelypredictsreductionintumorgrowthratefollowingVPAtreatment
in patient tumor xenografts. MATCH uses genomic analysis with in vitro testing of patient tumors to
select optimal drug regimens before clinical trial initiation.
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Introduction
Matching treatments to patients who will most beneﬁt using
streamlined computational and biochemical analyses will
enable effective clinical trial design for the many drugs
currently available (Adjei et al, 2009; Dancey et al,2 0 1 0 ;
Freedman et al, 2010). An efﬁcient approach for accurate
identiﬁcation of cancer patients who will beneﬁt from a
speciﬁc therapy prior to clinical trial initiation will enable
optimal selection of patients for clinical trials. The beneﬁts of
identifying the right target population for a drug include (1)
improved patient response, (2) minimization of time lost
treating patients non-responsive to therapy, (3) avoiding side
effects in people who will not respond, and (4) smaller sample
sizes needed for clinical trials because of largerexpected effect
sizes. As the pharmaceutical industry estimates that there are
over 800 agents and biologics in use or under development for
treatment of human malignancies, knowing best how to target
these drugs to the cancer patients who will beneﬁt most is
critical (PhRMA, 2009).
Historically, most clinical trials evaluate a therapeutic
regimen on an unselected patient population, measuring
efﬁcacy based on the response in the entire group. Therefore,
these studies may fail to identify a signiﬁcant response rate
when a drug is effective in only a subset of patients (Bast and
Hortobagyi, 2004). By incorporating prior knowledge about
drug sensitivity or the underlying signaling pathways driving
cancer progression, relevant subpopulations can be deﬁned
priortoaclinicalstudy,improvingthelikelihoodofobtaininga
signiﬁcant drug response (Bild et al, 2006; Downward, 2006;
Lamb et al, 2006; Dutta and Maity, 2007; Huang et al, 2007;
Rhodes et al, 2007; Du et al, 2009). Given the heterogeneity of
cancer, the future of personalized medicine is to have a large
number of drugs to choose from, each associated with a
biomarker that predicts cancer responsiveness. For example,
B15–20% of breast cancers have HER2 ampliﬁcation, which
corresponds to high levels of responsiveness to trastuzumab
(Barron et al, 2009; Coulson et al, 2010). Without knowing the
relevant population of breast cancer patients to treat with this
inhibitor, the drug would not have had signiﬁcant improve-
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available tools to predict patient sensitivity, such as FISH for
HER2 ampliﬁcation, we still are not able to perfectly predict
who will respond. As an example, approximately one third of
breast cancer patients with ampliﬁed HER2 do not respond
to trastuzumab, in part due to deregulation of downstream or
parallel pathway components such as PTEN or PI3K (Marty
et al, 2008; Stemke-Hale et al, 2008).
With the increasing use of high-throughput technologies in
the study of cancer, genomic approaches are ﬁnding their
way into the oncologists’ toolkit (Neve et al, 2006; Tinkeret al,
2006; Massague, 2007; Foekens et al, 2008; Gusterson, 2009;
Sotiriou and Pusztai, 2009). The majority of commercially
available genomic assays focus on prognosis but not predic-
tion(Desmedt etal,2008;Haibe-Kainsetal, 2008; Sotiriouand
Pusztai, 2009). Therefore, these tests provide risk of recur-
rence but do not predict response to particular chemotherapy
or non-chemotherapy drugs. For most drugs newly entering
the clinical trial pipeline, we still lack the means to rationally
and efﬁciently choose an optimal drug regimen targeted
toward the characteristics of a speciﬁc tumor, thus impeding
the promise of personalized medicine (Desmedt et al, 2008).
While creating a predictive drug response signature using
actual patient response data is ideal, this approach cannot be
used before a drug is tested in a large number of people with
different kinds of cancers. Recent studies have identiﬁed
subsets of patients characterized by gene expression proﬁles
indicating drug sensitivity, and some have translated these
ﬁndingsintoclinicaltrials(Changetal,2003;Lambetal,2006;
Huangetal,2007;Lamb,2007;Rhodesetal,2007;Haibe-Kains
et al, 2008). One genomic approach is the ‘Connectivity Map,’
which includes a compendium of gene expression proﬁles
based on chemical and genetic perturbations (Lamb et al,
2006). However, individual assessments of optimal drug
sensitivity in cancer patients using high-throughput proﬁling
andtherelationship ofthese proﬁlestodrug response inactual
human tumors have not been thoroughly evaluated. Selecting
effective drugs by leveraging both genomic and focused
preclinical testing with actual patient tumors streamlines the
identiﬁcation of optimal therapeutic regimens.
In this study, we make progress toward this goal by using
genomic methods to identify drugs that will be effective for
individual tumors. We provide a method, which we call
MATCH (Merging genomic and pharmacologic Analyses for
Therapy CHoice), to determine the individuals most likely to
beneﬁt from a drug prior to a clinical trial. We use the histone
deacetylase(HDAC)inhibitor valproicacid(VPA)asourproof-
of-principle. We focus on VPA because its optimal target
population is not well deﬁned, it is readily available, oral,
inexpensive, and has relatively low toxicity. VPA also happens
to be attractive from an informatics standpoint because it can
be tested in vitro without needing metabolic activation and
there are sufﬁcientsamples inthe Connectivity Mapto achieve
a robust signature on leave-one-out cross-validation (LOOCV)
analysis.MATCHleveragesextensivegeneexpressiondataand
biochemical validation to rationally match drugs to patients.
We ﬁrst use a genomic approach to predict drug sensitivity
across cancer types and between cancer and normal tissue
to identify those cancers most likely to respond to a drug.
We then focus on breast cancer and examine VPA sensitivity
for general breast cancer subtypes and for individual tumors
within these subtypes. Importantly, this approach allows
for drug response characterization in actual human tumors
and may represent a more accurate assessment of drug
sensitivity than the use of cell lines alone. In silico validation
of MATCH’s ability to link drugs to optimal target cancer
phenotypes is provided by the characterization of a B-RAF
inhibitor that has been proven in vitro and in the clinic to
effectively treat melanoma: predictions by MATCH correspond
to the observed clinical activity of this B-RAF inhibitor. As the
ideal target population for VPA is unknown, the accuracy of
genomic drug sensitivity predictions for VPA is veriﬁed in vitro
with breast cancer cell lines grown in two-dimensional (2D)
culture. We then use patient tumors, grown in both three-
dimensional (3D) cultures and mouse xenografts, to further
conﬁrm accurate drug sensitivity predictions for individual
samples. From these analyses, VPA is identiﬁed as a potential
therapy in the treatment of aggressive breast cancers, and
our drug response signature is shown to predict in vivo
response to VPA in individual patient tumors. More generally,
MATCH provides an efﬁcient methodology for determining the
cancer patients most likely to respond to a particular drug
without any prior knowledge of drug mechanism or target
population.
Results
Flowchart of MATCH approach for optimal patient
selection
Figure1outlinestheMATCHapproachforchoosinganoptimal
target patient population for a drug. We ﬁrst generate a
genomic signature of cellular response to the drug by using
cancer cell lines treated with drug or a placebo vehicle. Gene
expression between the untreated and treated cells is then
compared to identify genes consistently reﬂective of drug
response, and those genes are used to generate the predictive
drug response signature. Following internal and external
computational validation, the signature is used to predict drug
sensitivity in data sets with multiple tumor types in order to
determine the cancer types with little or no sensitivity that
should be excluded from further testing. If desired, this
analysis can be performed for actual patient tumors, which
may provide a more accurate measure of drug sensitivity than
cell lines, which often gain additional genetic changes
comparedwith the primarytumor followinggrowth in culture.
Next, the signature is used to predict drug sensitivity in data
sets with matched tumorand normal tissue in order to exclude
those tumor types where there is no signiﬁcant increase in
tumor sensitivity compared with normal tissue. Tumors in
such tissues wouldlikelyhave limited sensitivity to drug given
no increase from baseline tissue response levels, and perhaps
even show unacceptable toxicity at pharmacologically rele-
vant doses of the drug if high baseline response is seen. Once
the optimal target cancer is identiﬁed, projection of the
signature into data sets of that cancer type allow comparisons
of drug sensitivity across subtypes deﬁned by established
prognostic or predictive features, such as estrogen receptor
(ER) or HER2 status for breast cancer, histologic type for lung
cancer, and grade or MSI status for colon cancer. In vitro
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sensitive to drug in genomic analyses using standard dose-
responsiveness testing of established cell lines in culture,
which can be accomplished in a matter of days. If that step is
successful, further validation is performed using a panel of
fresh patient tumor samples grown in relevant in vitro
conditions, such as 3D matrix for breast cancer. If both of
these models show a relationship between predicted and
actual sensitivity, then the genomic signature can be used to
identifyanoptimaltargetpopulationforclinicaltrialinitiation.
Generation of drug response signature
Gene expression proﬁles of cancer cells following drug
treatment are a useful tool to better understand cellular
changes reﬂective of drug treatment. These expression
proﬁles can be used to identify genes reﬂective of drug
response: tumors with genes upregulated that turn off
following drug treatment are most likely to be sensitive, and
vice versa. One resource that has extensively cataloged genes
modulated byspeciﬁc drug treatments is the Connectivity Map
(Lamb et al, 2006). We generated a response signature for VPA
using samples from the Connectivity Map build 1 as the
trainingset. Geneexpression microarraydata from treated and
untreated cells were analyzed using a binary regression
algorithm to determine the genes that best distinguished
treated from untreated samples. Parameters for the binary
regression were optimized to maximize the consistency and
robustness of predictions within the training set. Internal
consistency and robustness of the signature was measured by
LOOCV, a processinwhich each sample is successively left out
of the training set and a model is ﬁt to the remaining samples
and then applied to the left out sample to obtain a prediction.
Preﬁlteringofgeneexpressiondataandnumberofgenesinthe
signatures were optimized to maximize the accuracy of
these predictions. The VPA signature used 200 probes,
which represent 188 unique genes, because some genes have
more than one probe on the microarray. The heatmap
and LOOCV graph for the VPA signature are shown in
Figure 2A and B.
We validated the accuracy and sensitivity of the signature in
twoways.First,anexternalandindependentdatasetwasused
inwhich normal ovarian theca cells weretreatedwith VPAora
control agent, and RNA from these cells were placed onto
microarray. Our analyses show a change in gene expression in
the VPA-treated cells compared with controls, further validat-
ing the accuracy of our signature (Figure 2C). Speciﬁcally, the
predicted sensitivity dropped from a mean of 0.77 before
treatment to 0.05 after treatment (P¼0.0002).
Second, weapplied the VPA signatureto 169 samples from 9
batches of the Connectivity Map build 2 that had at least one
sample treated with VPA and one sample treated with another
drug. The predictions are shown in Figure 2D. Untreated cells
and cells treated with random drugs show signiﬁcantly more
predicted sensitivity to VPA than cells treated with VPA or
otherHDACinhibitors(Po0.0001).Thevariation inprediction
in VPA-treated cells is due to different doses, with increasing
dose of VPA correlating to a decrease in predicted sensitivity
(Figure 2E). Based on the ROC curve, the optimal cutoff for
VPA sensitivity is B0.5, with an AUC of 0.86 (Figure 2F).
In order to better understand the meaning of the VPA
signature,weperformedaGeneOntologyanalysisofthegenes
in the signature using http://gather.genome.duke.edu. Gene
Ontology categories with a disproportionate number of genes
in the signature are shown in Figure 2G. In particular, genes
involved in cell growth and communication (FGFR1, IGF2,
PDGFRB, TGFB2, and MET) and genes involved in cell-cycle
regulation (CDK2, CDK10, and CDKL1) are dysregulated
by VPA.
Rational determination of relevant tumor type
for drug treatment
We examined the pattern of predicted sensitivity to VPA across
different types of cancer in order to identify the tumors most
likely to respond to drug treatment (Figure 3A). Speciﬁcally,
usingtheVPAsignaturedeﬁnedabove(Figure2),wepredicted
Figure 1 Flowchart of streamlined method to identify target population
for a drug.
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lines (https://array.nci.nih.gov/caarray/project/woost-00041).
These cancer cells were placed onto microarray as a group
and can be used to compare proﬁles across over 40 different
tumor types. The results highlight the broad variation in
responsiveness of different tumor types and show that speciﬁc
Figure2 VPAsignature.(A)TheheatmapcolumnsaretheConnectivityMapsampleswiththe10controlsontheleftand5treatedsamplesontheright.Eachrowisaprobe
in the signature. Red indicates upregulation and blue indicatesdownregulation ofthe gene. (B) LOOCV from the Connectivity Map training sample. Blue samples (1–10)are
thecontrol samples.Redsamples(11–15)arethe VPA-treatedsamples.(C)Bargraphofmeanandstandard errorofpredictedVPAsensitivity onovariantheca cellsbefore
and after treatment with VPA. (D) Graph of predicted sensitivity to VPA in Connectivity Map samples from nine independent batches. Samples are grouped as untreated
controls, samples treated with a drug other than an HDAC inhibitor, samples treated with an HDAC inhibitor other than VPA, and samples treated with various doses of VPA.
(E) Graph of sensitivity predictions versus actual treatment dose for Connectivity Map samples treated with various doses of VPA. The line is a best-ﬁt sigmoidal curve
excluding the two outliers. (F) ROC curve based on data from Figure 2D comparing VPA-treated samples with samples that were untreated or treated with a non-HDAC
inhibitor. (G) Doughnut plot of the Gene Ontology terms for the genes in the VPA signature with Bayes factor 42. Bayes factor for each term is given on the doughnut.
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average predicted response and others, such as brain, ovarian,
and melanoma, have low predicted response. Therefore, this
approach provides a mechanism to rapidly assess predicted
drug sensitivity between different tumor types in order to
exclude from further study those with gene expression
patterns reﬂective of little drug sensitivity and to focus
on those with subpopulations predicted to be sensitive to
the drug.
While assessing predicted drug sensitivity betweendifferent
tumor types is an important ﬁrst step in determining the
optimal tumor types for a speciﬁc therapy, these results must
be taken in the context of tissue type. The goal is to identify
tumor-speciﬁc response to drug and minimize tissue-speciﬁc
effects. To this end, we used a gene expression data set
comprised of matched normal and tumor tissue proﬁles.
In order to minimize artifact such as batch effect, we looked
within a single previously published data set containing
several different types of cancer (Yu et al, 2008), although
other data sets were compared and similar results were found
(data not shown). The average sensitivity within each type of
cancerandnormal isshowninFigure3B.Signiﬁcantly, thereis
high correlation between the cancer cell line (Figure 3A) and
patienttumorgeneexpressionpredictions(Figure3B),thereby
conﬁrming the drug response patterns identiﬁed in the cancer
cell lines. Further, breast and lung cancers were signiﬁcantly
more sensitive to VPA than the corresponding normal tissues,
P¼6 10
 6 and P¼0.005, respectively. Liver (P¼0.14), eso-
phageal (P¼0.3), colon (P¼0.22), and thyroid (P¼0.36)
cancers did not differ in sensitivity from the corresponding
normal tissue. These results areconsistent with priorresearch;
for example, VPA is known to be toxic to normal liver cells
in vitro and in vivo, to cause gastrointestinal-related side
effects, and can cause hypothyroidism with long-term use
(Fisheretal,1991;Gauetal,2010).Wechosetofocusonbreast
cancer for further study due to its high predicted sensitivity to
VPA compared with other cancers and its highly signiﬁcant
sensitivityintumortissuecomparedwithnormalbreasttissue.
Meta-analysis of drug sensitivity patterns
in breast cancer phenotypes
We then examined patterns of sensitivity across different
phenotypes of breast cancer. We applied the VPA response
signature to each of the 1803 human breast cancer samples in
11 large independent data sets of microarray data from snap-
frozen tumors (Supplementary Table S1). A cutoff of 0.5 was
then used to predict sensitivity or resistance in all cases.
Homogeneity of the data sets was tested by ANOVA limited
to each breast cancer subtype across data sets for the
VPA response signature (Supplementary Figure S1). Overall,
the data sets were homogeneous in the relative predicted
sensitivityofeachsubtypetoVPA,thedifferencesinmeanVPA
sensitivity between data sets within each subtype were o0.2,
mediansweregenerallyonthesamesizeof0.5,andremovalof
individual datasets did notimprovehomogeneitysigniﬁcantly
or affect conclusions. Therefore, all 11 data sets were used.
Results from predictions of all data sets were merged and
sorted by molecular subtype (upper color bar on Figure 3C),
providing an overview of the predicted responsiveness of each
subtype to each drug. In all, 57% of basal tumors, 57% of
HER2-liketumors,42%ofluminalAtumors,57%ofluminalB
Figure 3 Predictions across cancer types and subtypes. (A) Box-whisker plotfor
predicted VPA sensitivity across GSK cell lines for epithelial cancers. Median is
indicated by a horizontal line. The box gives the interquartile range, and the error
bars indicate thetotalrange.(B) Box-whisker plot for VPA sensitivity across cancer
types in GSE5364. Boxes for normal adjacent tissue are checkered. Median is
indicated by a horizontal line. The box gives the interquartile range, and the error
bars indicate the total range. (C) Heatmap of samples from 11 breast cancer data
sets, divided by intrinsicsubtype,with the predicted response to VPA displayed asa
color, with red representing a high predicted response, and blue a low predicted
response. Each column is an individual sample, and the heterogeneity of predicted
response to VPA within and between subtypes is clearly visible. The percent of
samples with predicted sensitivity 40.5 is given below the heatmap.
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sensitive to VPA. Overall, 51% of breast tumors are predicted
to be sensitive to VPA, with signiﬁcant heterogeneity within
subtypes. Overall, more aggressive breast cancer subtypes
such as basal, HER2-like, and luminal B have higher levels of
predicted sensitivity. This ﬁnding is in contrast to other drugs
such as fulvestrant, an ER pathway antagonist, which shows
subtype response speciﬁcity for ER-positive subtypes (luminal
A, luminal B, and normal-like) (Supplementary Figure S2).
Therefore, even within a particular breast cancer subtype,
there remains varied predicted sensitivity, highlighting the
importance of individualized predictions.
In silico validation of the MATCH approach
using a drug with a known target population
While VPA is attractive to study because of the need for
identiﬁcation of a target population for ongoing clinical trials,
we also wanted to validate MATCH using a drug with a
well-deﬁned target population. Gene expression analysis on a
data set of sensitive melanoma cells treated with a B-RAF
inhibitor, PLX4032 (GSE20051) enabled generation of a
genomic signature (Joseph et al, 2010). Importantly, we use
PLX4032 to validate the ability of our genomic approach to
identify responsive cancers, as we know from clinical trials
that PLX4032 has an 80% response rate in melanoma with
mutant B-RAF(Flaherty et al, 2010). Adrug responsesignature
was developed from treated and untreated cells using the
approach detailed above. The signature for PLX4032 yielded a
signature with 200 probes representing 157 unique genes. The
heatmap and LOOCV graph for the B-RAF inhibitor signature
are shown in Figure 4A and B. We then validated the ability of
the B-RAF inhibitor signature to predict sensitivity in cancer
cell lines, and show signiﬁcant response in tumor cells with
activating B-RAF mutations versus those without mutation
(Supplementary Figure S3A).
We projected this signature into the panel of tumor cell lines
and identiﬁed high predicted sensitivity to the B-RAF inhibitor
PLX4032 in cell lines from melanoma, thyroid cancer, and
GIcancersandlowpredictedsensitivityincelllinesfromsmall
cell lung cancerand neuroblastoma (Figure 4C). This inhibitor
is known to be active in tumors with the B-RAFV600E
mutation, and our ﬁndings are consistent with published data
Figure 4 PLX4032 signature and validation. (A) The heatmap columns are the GSE20051 samples with the ﬁve controls on the left and ﬁve treated samples on the
right. Each row is a probe in the signature. Red indicates upregulation and blue indicates downregulation of the gene. (B)LOOCV from the GSE20051 training set. Blue
samples (1–6) are the control samples. Red samples (7–12) are the PLX4032-treated samples. (C) Box-whisker plot for predicted PLX4032 sensitivity across GSK cell
lines for epithelial cancers stratiﬁed by cancer type. (D) Box-whisker plot for PLX4032 sensitivity across skin cancer types and normal skin in GSE7553. (Cancer and
normal types with two or fewer samples were excluded.) Median is indicated by a horizontal line.
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neuroblastomadoesnothaveactivatingmutationsinB-RAFor
in other members of the PI3K/RAS/RAF/MAPK cascade;
therefore,targetingB-RAFinthesetumorsmaynotbeeffective
(Dam et al, 2006). Also, RAF activation in small cell lung
cancer, in contrast to other cancers, has been shown to be
detrimental to cancer cell survival (Ravi et al, 1998). On the
other hand, PLX4032 is active in melanoma in clinical trials
and thyroid cancer in vitro, supporting the validity of our
in silico results (Flaherty et al, 2010; Kopetz et al, 2010; Xing
et al, 2011).
Next,wepredictsensitivityofpatienttumorscomparedwith
normal tissue to assess drug speciﬁcity. Again, we see that
tumor types identiﬁed in our initial analysis across a panel
of cancer cell lines show high tissue speciﬁcity in our analysis
of matched normal and tumor samples (Supplementary
Figure S3B). Further, as matched normal skin and melanoma
cells are not present in the previous data set, we compared
normal skin cells versus melanoma using an independent data
set and see signiﬁcant predicted sensitivity to the B-RAF
inhibitor in melanoma with little predicted sensitivity in
squamous cell cancer of the skin, basal cell cancer of the skin,
or normal skin (Po0.0001) (Figure 4D). Therefore, our
predictions of the optimal target population for the B-RAF
inhibitor correspond to the published and conﬁrmed target
populations. Together, these ﬁndings highlight the ability
of our in silico genomic approach to identify relevant tumor
types for speciﬁc drugs.
Finally, in order to better understand the meaning of the
PLX4032 signature, we performed a Gene Ontology analysis of
the genes in the signature using http://gather.genome.duke.
edu. Gene Ontology categories with a disproportionate
number of genes in the signature are shown in Supplementary
Figure S3C. In particular, genes involved in ribosome biogen-
esis and rRNAmetabolism (BRIX1, EXOSC2, EXOSC4), protein
amino-acid dephosphorylation (DUSP4, DUSP6, DUSP14,
and CDC25A), and regulation of the cell cycle (CCND1,
CCNE1, E2F4, and MYC) are dysregulated by PLX4032.
In vitro validation of drug response signature
predictions
While MATCH leverages genomic resources to guide
therapeutic selection for individual tumors in cases where a
drug’s idealtargetpopulation has notpreviously been deﬁned,
a rapid means to validate MATCH predictions is warranted.
One method to conﬁrm the accuracy of using drug response
signatures is to use in vitro dose-response studies on cancer
cell lines in which genomic analysis was used to predict drug
sensitivity. After projecting the drug response signatures in a
panel of breast cancer cell lines, we correlated predicted and
actual drug sensitivity. Following a comprehensive dose-
response analysis, we calculated the effective concentration
at which the growth rate is inhibited by 50% (EC50) for each
cell line and correlated this EC50 to the predicted sensitivity of
that cell line to drug treatment. As shown in Figure5, thereis a
signiﬁcant correlation between actual (as determined by a cell
line’s EC50) and predicted sensitivity for VPA (P¼0.013).
No cell line predicted to be resistant (predicted sensitivity
o0.5) had an EC50 within three-fold of clinically achievable
concentration of VPA.
3D validation of drug response signature
predictions
Because breast cancer cell lines are known to have ‘drifted’
and, thus, maintain very different expression patterns and
phenotypes when compared with actual patient tumors, we
validatedthegenomic predictions forthisagentin othermodel
systems: 3D culture of patient tumors and xenografts (Kenny
et al, 2007). First, we used short-term, 3D cultures of patient
breast tumor samples both from primary tumors and from
pleural effusions. The 3D culture microenvironment more
closely resembles the in vivo cellular microenvironment and
provides a more biologically relevant growth setting than
standard 2D microenvironments (Bissell and Labarge, 2005;
Grifﬁth and Swartz, 2006). Importantly, this approach allowed
for growth of ER-positive tumors, which are difﬁcult to
establish in xenograft models.
For 3D culture, the cytoxic effect of VPA treatment on
the tumor organoids was assessed by light microscopy
(a representative example is shown in Figure 6A). As shown
in a representative example of a triple negative (basal-like by
microarray) tumor predicted to be sensitive to VPA, tumor
organoids treated with VPA exhibited reduced structural
integrity and increased cellular scatter with increasing
concentrations of VPA. A marked increase in ethidium
bromide uptake was observed concomitantly with the loss of
organoid integrity, demonstrating a cytotoxic effect of VPA on
the primary tumor organoids.
A dose-response assay was carried out to determine the
relative sensitivity of tumor organoids to VPA treatment.
From the dose-response curves for each tumor, we determined
the EC50. Individual tumors of the more aggressive subtypes
of breast cancer (basal-like, HER2-overexpressing, and lumi-
nal B) show higher responsiveness than the less aggressive
subtypes (luminal A and normal-like). As shown in Figure 6B,
there is a statistically signiﬁcant correlation between
Figure 5 Correlation of actual response to targeted therapeutics and predicted
response from drug response signatures. Breast cancer cell lines were treated
with VPA for 96h and proliferation was assayed using a standard MTT
colorimetric method. Scatter plot shows the degree of correlation between
proliferation inhibition (EC50) and predicted sensitivity for each cell line.
Source data is available for this ﬁgure at www.nature.com/msb.
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studies validate both the genomic predictions and the utility of
3D culture of primary tumor samples for a rapid, efﬁcient, and
relevant preclinical analysis of drug sensitivity.
In vivo validation of drug response signature
predictions
Tofurtherassesstheaccuracyofour predictions,weusedmice
with tumor-speciﬁc xenografts derived from human breast
cancers. For this analysis, the gene expression patterns of
patient tumors were analyzed using our drug response
signature to VPA. We selected different patient tumors
predicted to have high or low sensitivity to VPA (Figure 7A)
to test our prediction in the corresponding mouse xenograft
models generated from these same tumors.
As shown in Figure 7B, the three tumors predicted to be
sensitive to VPA show a highly signiﬁcant smaller size when
treated with VPA compared with placebo (Figure 7B,
Po0.0002 for each tumor). No change in tumor size after
treatment with VPA was seen in the tumors predicted to be
resistant (Figure 6B, P¼0.96 and P¼0.81). This is an important
ﬁnding, as it suggests that this genomic approach can
accurately predict the response of an individual patient’s
tumor to a targeted therapy. We next compared conventional
chemotherapy with VPA treatment in one tumor predicted
to be sensitive to VPA. Each group included 10 mice. In
this experiment, VPA decreased tumor growth signiﬁcantly
more than doxorubicin (Po0.0001) (Supplementary
Figure S4), further highlighting the potential effectiveness of
VPA to inhibit tumor growth in vivo in a sensitive tumor.
Discussion
Clinical trial designs using unselected populations often fail to
identify signiﬁcant responses that may be relevant only to a
subset of tumors.By using prior information, clinical trials can
be rationally designed to test therapeutic regimens in tumor
types identiﬁed asmost likelyto be responsive. However, prior
information is not always available. Therefore, we developed
MATCH as an unbiased genomic approach to predicting
drug sensitivity in individual tumors.
MATCH leverages the large amount of publicly available
genomic data to investigate optimal targeted therapy for
individualcancers.TheexampleofVPAinbreastcancershows
the superiority of individualized genomic predictions over
simply using traditional cancer subtypes. Current methods to
classify breast cancer phenotypes utilize tumor pathology and
signaling pathway status to place the tumor into a molecular
subtype (Perou et al, 2000; Sorlie et al, 2001, 2003; Hu et al,
2006; Desmedt et al, 2008; Wirapati et al, 2008; Parker et al,
2009). However, the existing molecular subtypes are not
ideal as the sole categorization for deﬁning breast cancer
therapy, as heterogeneity exists within each subtype (Di
Cosimo and Baselga, 2010; Foulkes et al, 2010). In fact, we
arelearningthatthereisincreasedcomplexityamongsubtypes
in clinical courseand responseto therapy. Forexample, HER2/
ERBB2-overexpressing tumors differ in their natural history
and/or response to therapy based on lymphocyte-associated
genes, PTEN status, and PI3K pathway status (Alexe et al,
2007; Rody et al, 2009; Esteva et al, 2010). Thus, signiﬁcant
heterogeneity remains uncharacterized even within breast
cancer subtypes, highlighting the need for approaches
investigating drug sensitivity or clinical phenotypes at the
individual patient level.
Figure 6 Patient tumor cell sensitivity to VPA in 3D culture. Primary tumor
and pleural effusion-derived breast cancer cells were embedded in Matrigel
and treated with VPA for 96h. (A) The effect of VPA was assessed by light
microscopy (right panel) and ﬂuorescent dye (left panel) to identify live (green)
and dead cells (red). (B) Correlation of EC50 of VPA and predicted response
from drug response signatures in the fresh tumor samples grown in 3D. Source
data is available for this ﬁgure at www.nature.com/msb.
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aggressive breast cancer subtypes, our studies show that there
is great variation in sensitivity of patient tumors to treatment
with VPA alone but that there is a deﬁnable population of
breast tumors that are markedly sensitive to VPA. VPA is
known to be a HDAC inhibitor, a class without any well-
deﬁnedbiomarkersofresponse.VPAisofconsiderableinterest
because it is oral, already FDA-approved for treatment of
epilepsy, and well tolerated over the long term. The low
toxicity of VPA makes this drug an ideal candidate to further
assess its potential in the treatment of selected tumors within
aggressive breast cancer subtypes, such as triple negative
tumors. VPA is currently being studied in clinical trials against
breast, lung, ovarian, thyroid, melanoma, prostate, and
cervical cancers (Michaelis et al, 2007). The fact that this drug
is being tested against so many different cancers without a
clear indication of potential efﬁcacy highlights the need for a
more targeted approach to ﬁnding the populations of patients
who will respond. For example, trials of another HDAC
inhibitor, SAHA, in lung cancer have shown stable disease
but no responses, perhaps due to the small number of subjects
receiving therapeuticdoses (Vansteenkiste et al, 2008; Traynor
et al, 2009). The ability to increasetrial efﬁciency by excluding
people who will not respond could improve such trials. By
using MATCH to couple personalized computational predic-
tion with in vitro and in vivo validation work, as presented in
this study, a systematic methodology for streamlining identi-
ﬁcation of optimal therapeutic regimens can be leveraged in
the clinical setting. We use the genomic predictions to guide
our pharmacological studies, followed by experimental
Figure 7 In vivo validation of computationally predicted responsiveness to VPA using human breast cancer xenografts. (A) Predicted sensitivity of ﬁve breast tumors
(four basal and one luminal) to VPA. The gene expression patterns of the patient tumors were analyzed using in vitro drug response signatures to VPA. (B) In vivo
response to VPA treatment on xenografts generated from the primary tumors in (A). Blue and red lines: VPA group; black line: saline control group. Each group had ﬁve
mice. Tumor growth rates were plotted as the mean tumor volumes of each group±s.e.m. Source data is available for this ﬁgure at www.nature.com/msb.
MATCH
AL Cohen et al
& 2011 EMBO and Macmillan Publishers Limited Molecular Systems Biology 2011 9validation in actual patient tumor cells to determine clinical
signiﬁcance before initiating a clinical trial. We then rapidly
verify the accuracy of these predictions using 2D in vitro cell
lines and 3D cell cultures generated from fresh tumors. In the
VPA example, we found signiﬁcant correlation between
predicted and actual sensitivity in all experimental conditions.
MATCH has some limitations. First, effective doses of drugs
in vitro may not be the same as in vivo due to factors such as
increased protein binding in culture media or organ metabo-
lism. Thus, MATCH gives the relative sensitivity of individual
tumors but cannot determine absolute doses for use. Second,
MATCH cannot predict all off target effects and side effects of
drugs. Third, not all tumors predicted to be sensitive by
MATCH will be sufﬁciently sensitive to clinical doses of drugs.
MATCH is useful for identifying patient populations most
likely to respond (or not) to a drug. Identifying relevant
populations for a drug boosts the proportion of possible
responders in a trial population, decreasing the chance of
falsely negative trials.
MATCH leverages high-throughput pharmacogenomic
and individual-based tumor drug response analyses, and
serves to identify the appropriate cancer patients for speciﬁc
drug therapies. This rational approach to drug selection has
the potential to streamline preclinical testing, optimize clinical
trial design, and identify clinically useful biomarkers early in
drug development.
Materials and methods
Calculating drug sensitivity
The VPA response signature was deﬁned using the Connectivity Map
build 1 (Lamb et al, 2006). The PLX4032 signature was deﬁned using
samples from GSE20051 (Joseph et al, 2010). A detailed description of
the signature generation methods can be found at http://io.genetics.
utah.edu/ﬁles/bildres.Inbrief,Mas5normalizedgeneexpressiondata
fromtheConnectivityMapwebsitewerelognormalizedandthenused
as the training set in the analysis. Each data set was also Mas5
normalized and then log transformed. Following normalization,
signature and data sets were quantile normalized, and 25% of probes
on the microarrays with the lowest expression and lowest variability
were preﬁltered from the analysis. Distance weighted discrimination
standardizationwasusedtocorrectforbatcheffectsbetweendatasets.
A Bayesian binary regression algorithm was then used on the training
set to generate a list of probes and weights relative to the ﬁrst principle
componentfor calculating a metagenescore that is then converted to a
probability. The probability output from the binary regression model
was subtracted from one, so that probabilities closer to one indicated
higher probability of sensitivity to the drug (Bild et al, 2006).
Parameters were optimized to minimize the P-value for a t-test
comparing the predictions of the treated and untreated samples in the
training set in the LOOCV analysis. To compare independently
collected and processed data sets, we log normalized and then linearly
transformedthebinaryregressionoutputforeachdatasetandforeach
signature to span from 0 to 1. To enable complete reproduction of our
results, the input ﬁles, output ﬁles, and the binary regression program
used in this study are available at http://io.genetics.utah.edu/ﬁles/
bildres. The binary regression program is also available via a web
interface through a Genepattern module at http://genepattern.
genome.duke.edu/signature/. Genes and probes comprising the VPA
response signature are found in Supplementary Table S2. Forsignature
validation, CEL ﬁles were downloaded from GEO GSE1615, which
contain gene expression data for human ovarian cells before and after
treatment with VPA, GEO GSE7553, which contains gene expression
data for various skin cancers and normal skin, and from Connectivity
Mapbatches2,35,44,56,63,70,626,757,and767(Woodetal,2005).
Study population and analysis of expression data
for multiple cancer types
CEL ﬁles were downloaded from GEO for data set GSE5364, which
containgeneexpressiondatafortumorandadjacentnormaltissuesfor
breast, colon, esophagus, lung, liver, and thyroid cancers, and from
CaBIG for the woost-00041 data set, which contains gene expression
data from over 300 different cell lines provided by Glaxo-Smith-
Kline (GSK), https://array.nci.nih.gov/caarray/project/woost-00041
(Yu et al, 2008). All data were mas5 normalized, and samples with a
ratio 43 between probes at the 30 and 50 end of GAPDH were
considered potentially degraded and excluded from further analysis.
We excluded sarcomas and hematopoietic malignancies from our
analysis as our signatures are generated with epithelial cells.
VPA sensitivity predictions were then generated as described above.
For duplicate and triplicate samples in the GSK panel, ﬁnal predictions
were averaged.
Study population and analysis of expression data
for breast cancer subtypes
Breast cancer samples from 11 microarray studies were employed in
this analysis (Supplementary Table S1). Duplicate samples from GEO
data sets gse6532, gse7390, and gse3494 and cell line and normal
samples from gse7904 were removed. As not all public data sets had
clinical annotations, intrinsic breast cancer subtypes were assigned as
described previously (Sorlie et al, 2001). Brieﬂy, a training set of 259
samples representing the ﬁve subtypes (luminal A, luminal B, HER2-
overexpressing, basal-like, and normal-like) and 306 genes were used
to build a corresponding set of ﬁve centroids (Hu et al, 2006). Features
were assigned using Entrez Gene identiﬁers and duplicate identiﬁers
werecollapsedtothemean.Eachtestcasewasthencomparedwiththe
ﬁve standardized centroids using Spearman’s rank correlation and
assigned the subtype of the nearest centroid.
Dose-response assays
Breast cancer cell lines obtained from ATCC (HCC1806, HCC1428,
HCC1143, BT549, BT474, MDA-MB-361, MDA-MB-435s, MDA-MB-231,
MDA-MB-453, SKBR3, ZR75, CAMA I, MCF7, Hs578t, T47D) were
seeded in 384 plates (NUNC) in MEBM media (Lonza) containing 5%
fetal bovine serum (GIBCO), at a density to yield 80% conﬂuency in
control treated wells at 96h post-treatment (as determined by growth
curves). After 24h, VPA (Calbiochem) was added at 10 doses ranging
from 64 to 0.25mM. A BIOMEK 3000 (Beckman Coulter) robot was
used to seed the cells and dispense the drug. After 96h, CellTiter-Blue
Reagent (Promega) was added to test cell viability. After 2h of
incubation at 371C, the ﬂuorescence was recorded (560(20)Ex/
590(10)Em) using a Victor
3V 1420 Multilabel Counter (Perkin-Elmer)
plate reader.
Breast cancer pleural effusion collection, growth
in 3D cultures, and drug response assays
All research involving human samples have been approved by the
authors’ institutional review board. With informed consent, breast
tumor samples were collected from patients at the University of Utah.
After obtaining written informed consent, pleural effusion samples
were collected from excess ﬂuid obtained at the time of therapeutic
thoracenteses or solid tumor samples were collected from mastec-
tomies or lumpectomies. Malignant cells from the pleural effusion or
solidtumorswereeitherusedtoisolateRNAorgrownin3Dculturesto
form organoid structures. Prior to embedding in BD Matrigel Matrix,
GrowthFactorReduced(BDBiosciences),solidtumorswereincubated
overnight in tissue mix media, MEBM containing 10% fetal bovine
serum, collagenase type III (1500U/ml) (Worthington), and hyalur-
onidase (1000U/ml) (Sigma). The single cells from either solid tumor
or pleural effusion were then re-suspended in complete media and
plated in a 24-well ultra low attachment tissue culture plate for 24h at
371Ci n5 %C O 2 to form organoid structures. Cells were diluted in
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A total of 30ml was then seeded into a 96-well half-area assay plate at
10
4cells/well. After 24h, VPA was added at a range of dosages
determined by our drug response assay. After 96h, viability was
determined as above. Images were taken using an Olympus IX81-ZDC
DSU with ORCAER camera and Slidebook 5.0 software
In vivo drug treatment experiments
Triple negative breast cancers were obtained from Stanford University
Hospitalwithinformedconsent.Tumortissuewasfrozenondryicefor
RNA isolation and microarray analysis. Tumors were minced and then
implanted into the number 2 and/or number 4 mammary fat pads of
5–10 female NOD/SCID mice (NOD.CB17–Prkdc
scid/J, Jackson
Laboratory West). When tumor xenografts grew 45mm in diameter,
mice were stratiﬁed by tumor size and randomized into two or three
treatment groups of 5–10 mice each: (1) a VPA group, receiving daily
intraperitoneal administration of VPA (400mg/kg) for up to 4 weeks;
(2) a control group, receiving daily intraperitoneal administration of
control vehicle (sterile saline) for up to 4 weeks; and, in another set of
experiments, (3) a doxorubicin group, receiving intraperitoneal
administration of doxorubicin (2mg/kg) at time zero and at 3 weeks.
Tumors weremeasuredtwice aweek witha caliper intwo dimensions.
Tumor size (M) was calculated as M¼a
2b/2, where a is the maximum
width and b is the maximum length. Means of tumor volume in the
same treatment group were calculated, and growth curves were
established as a function of time. All animal care was in accordance
with Stanford University and IACUC guidelines.
Microarray data sets
All novel microarray data sets are posted on GEO under accession
GSE18331. CEL ﬁles for the cell lines used in the 2D culture
experiments have previously been made available as GSE3156.
All input ﬁles, program ﬁles, and output ﬁles are posted at http://
io.genetics.utah.edu/ﬁles/bildres. Affymetrix U133A 2.0 microarrays
were used according to the manufacturer’s protocols.
Statistics
Meanswerecomparedwitht-testsor withANOVAwithpost-test t-tests
usingBonferroni multiplecomparison testing,except where indicated.
Correlations were calculated using Spearman’s r. Drug-response
graphs are plotted as means with SEM, ﬁtted to an exponential curve,
and compared with MANOVA. We considered Po0.05 statistically
signiﬁcant. Calculations were done using MATLAB, R, and Graphpad
Prism version 4.02.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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